ADVFN Logo
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Mountain Crest Acquisition Corporation V

Mountain Crest Acquisition Corporation V (MCAG)

11.17
0.00
(0.00%)
Closed September 19 4:00PM
0.00
0.00
(0.00%)

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
11.17
Bid
10.54
Ask
11.37
Volume
-
0.00 Day's Range 0.00
10.47 52 Week Range 11.37
Market Cap
Previous Close
11.17
Open
-
Last Trade
Last Trade Time
-
Financial Volume
-
VWAP
-
Average Volume (3m)
2,036
Shares Outstanding
3,170,221
Dividend Yield
-
PE Ratio
-15.73
Earnings Per Share (EPS)
-0.71
Revenue
-
Net Profit
-2.25M

About Mountain Crest Acquisition Corporation V

Mountain Crest Acquisition Corp V is a blank check company. Mountain Crest Acquisition Corp V is a blank check company.

Sector
Blank Checks
Industry
Blank Checks
Headquarters
Wilmington, Delaware, USA
Founded
-
Mountain Crest Acquisition Corporation V is listed in the Blank Checks sector of the NASDAQ with ticker MCAG. The last closing price for Mountain Crest Acquisiti... was $11.17. Over the last year, Mountain Crest Acquisiti... shares have traded in a share price range of $ 10.47 to $ 11.37.

Mountain Crest Acquisiti... currently has 3,170,221 shares outstanding. The market capitalization of Mountain Crest Acquisiti... is $35.41 million. Mountain Crest Acquisiti... has a price to earnings ratio (PE ratio) of -15.73.

MCAG Latest News

Mountain Crest Acquisition Corp. V Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Reports on Form 10-Q and Makes Progress Towards Regaining Compliance

NEW YORK, Sept. 18, 2024 (GLOBE NEWSWIRE) --  Mountain Crest Acquisition Corp. V (the “Company”) (NASDAQ: MCAG), today announced that it received an expected deficiency notification letter from...

CUBEBIO Announces Business Combination Agreement With Mountain Crest V to Become Publicly Listed

NEW YORK, USA and SEOUL, Korea, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Mountain Crest Acquisition Corp. V, a Delaware corporation formed as a special purpose acquisition company (“Mountain Crest V”...

Mountain Crest Acquisition Corp. V Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Annual Report on Form 10-K and Quarterly Report on Form 10-Q

NEW YORK, July 24, 2024 (GLOBE NEWSWIRE) -- Mountain Crest Acquisition Corp. V (NASDAQ: MCAG, the “Company”) today announced that it received an expected deficiency notification letter from the...

CUBEBIO Co., Ltd. entered into terms relating to a potential business combination with Mountain Crest Acquisition Corp. V

NEW YORK, USA and SEOUL, Korea, May 02, 2024 (GLOBE NEWSWIRE) -- Mountain Crest Acquisition Corp. V, a Delaware corporation (“Mountain Crest V”), that is a Nasdaq-listed (Nasdaq: MCAG) special...

Mountain Crest Acquisition Corp. V Announces Listing Transfer to the Nasdaq Capital Market

NEW YORK, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Mountain Crest Acquisition Corp. V (Nasdaq: MCAG) (the “Company”) announced today that it has received approval from the Nasdaq Stock Market...

AUM Biosciences Doses First Patient in Phase 2 Clinical Trial of AUM001 in Metastatic Colorectal Cancer

SINGAPORE and BETHESDA, Md., May 30, 2023 (GLOBE NEWSWIRE) -- AUM Biosciences Pte. Ltd. (“AUM”), a global clinical-stage biotechnology company focused on discovering and developing precision...

AUM Biosciences to Participate in Inaugural EF Hutton Global Conference

SINGAPORE and BETHESDA, Md., April 26, 2023 (GLOBE NEWSWIRE) -- AUM Biosciences Pte. Ltd. (“AUM”), a global clinical-stage biotechnology company focused on advancing a pipeline of precision...

AUM Biosciences Receives FDA Orphan Drug Designation for AUM302 for the Treatment of Neuroblastoma

SINGAPORE and BETHESDA, Md., Nov. 30, 2022 (GLOBE NEWSWIRE) -- AUM Biosciences Pte. Ltd. (“AUM”), a global clinical-stage biotech company focused on discovering and developing precision oncology...

AUM Biosciences Receives Human Research Ethics Committee Approval to Commence Phase II Clinical Trial of AUM001 for Treatment of Metastatic Colorectal Cancer in Australia

SINGAPORE and BETHESDA, Md., Nov. 15, 2022 (GLOBE NEWSWIRE) -- AUM Biosciences Pte. Ltd. (“AUM”), a clinical-stage biotechnology company, advancing a clinical stage candidate and a broader...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.030.26929982046711.1411.3411.151111.18098277CS
40.363.3302497687310.8111.3710.81515611.08579323CS
120.171.545454545451111.3710.71203611.04775288CS
260.484.490177736210.6911.3710.47123810.98133304CS
520.54.6860356138710.6711.3710.4779610.91782148CS
156-0.83-6.9166666666712129.6990049.95735869CS
260-0.83-6.9166666666712129.6990049.95735869CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AAGRAfrican Agriculture Holdings Inc
$ 0.1224
(0.00%)
0
AADRAdvisorShares Dorsey Wright ADR ETF
$ 62.9381
(0.00%)
0
AADIAadi Bioscience Inc
$ 1.87
(0.00%)
0
AACIArmada Acquisition Corporation I
$ 9.75
(0.00%)
0
AACGATA Creativity Global
$ 0.5187
(0.00%)
0
AAGRAfrican Agriculture Holdings Inc
$ 0.1224
(0.00%)
0
AADRAdvisorShares Dorsey Wright ADR ETF
$ 62.9381
(0.00%)
0
AADIAadi Bioscience Inc
$ 1.87
(0.00%)
0
AACIArmada Acquisition Corporation I
$ 9.75
(0.00%)
0
AACGATA Creativity Global
$ 0.5187
(0.00%)
0
AAGRAfrican Agriculture Holdings Inc
$ 0.1224
(0.00%)
0
AADRAdvisorShares Dorsey Wright ADR ETF
$ 62.9381
(0.00%)
0
AADIAadi Bioscience Inc
$ 1.87
(0.00%)
0
AACIArmada Acquisition Corporation I
$ 9.75
(0.00%)
0
AACGATA Creativity Global
$ 0.5187
(0.00%)
0

Discussion

View Full Feed
tw0122 tw0122 2 minutes ago
Pump it up
TBIO
MiamiGent MiamiGent 3 minutes ago
Good observation, Red.
Ms Labonte Ms Labonte 4 minutes ago
The junkie$$ will fill em bid$$$ Let$$$$$ gooooooo$$$$$
RNAZ
jxyzobrien jxyzobrien 6 minutes ago
shane s on larry pesavento 130pm
Ms Labonte Ms Labonte 9 minutes ago
The flipper$$ will run out of ammo very quickly with massive per market pre$$ure coming $weet$$$
URE WEET
eagle8 eagle8 10 minutes ago
"But we would now like to do some more focused, faster path, tumor shrinkage endpoint trials. So we are, as we evaluate, I mean, we have so many opportunities in front of us now. Really, the challenge is choosing. Right? And so we we gotta steer ourselves, to the extent we can, towards that directio
NWBO
QuickCash4Me QuickCash4Me 10 minutes ago
If you think someone posting on this board is pumping/moving shares in any company, you’re delusional. The audience is so small, it can’t possibly have an impact one way or another. The only thing it can do is help someone that is following a company with their research.

I don’t und
AITX
SkeBallLarry SkeBallLarry 14 minutes ago
"Super" Happy *BirthDay*, Capgain " .. !!
Seminole Red Seminole Red 16 minutes ago
Trump on Gutfield last night was great.

its easy to see a communicator would make a much better President.

no notes, no teleprompter, no agenda, just down earth talking.
Zazaboy Zazaboy 16 minutes ago
chill out, u might wake your boyfriend.
BTCUSD
Ms Labonte Ms Labonte 18 minutes ago
Rolled up the 30’$$$ $weet$$ $moking it like a joint$$$$$
MOKING WEET
Ms Labonte Ms Labonte 21 minutes ago
FDA fa$t track on $tandby new$$$ $weet$$$
T TANDBY WEET
Stern is Bald Stern is Bald 22 minutes ago
Ok
FNMA
toohot toohot 25 minutes ago
Thank you for your monthly BIEL post. I see you’re still banging the table!

#1 Life is 10% what happens to you and 90% how you react to it.
Charles R. Swindoll
#2 If you have the facts, bang on the facts, if you have opinion bang on opinion, if you
BIEL
Ms Labonte Ms Labonte 27 minutes ago
Pre-market pressure $weet$$$$ Grab all you can at the$e level$$ a gift from heaven above$$$$$
E WEET
KeepItRealistic KeepItRealistic 29 minutes ago
$GNS no 🧠’er buy & hold for FAIR MARKET VALUE

$105m revenue 2024

Current Market Cap 19m

The revenue multiple, is a valuation metric used to estimate the value of a company based on its revenue.

In the education market, determining
GNS
KeepItRealistic KeepItRealistic 29 minutes ago
$GNS no 🧠’er buy & hold for FAIR MARKET VALUE

$105m revenue 2024

Current Market Cap 19m

The revenue multiple, is a valuation metric used to estimate the value of a company based on its revenue.

In the education market, determining
GNS
Ms Labonte Ms Labonte 29 minutes ago
Who will take u$ to heaven $weet$$$
Bristol Myers Squibb

AstraZeneca

Merck

Novartis

Roche

AbbVie

Johnson & Johnson

Accord Healthcare

Amgen

Astellas Pharma
WEET
Copilotdog Copilotdog 39 minutes ago
Filing to shut down American OTC this qtr. product no longer at any locations.
PSYCF
lovethatgreen lovethatgreen 42 minutes ago
The 500 share trades are odd but hardly nefarious and imo the stock is trading brilliantly with traders selling and buying .

Now the topic isnt labeled corruption now it's nefarious . Lol

If there was anything nefarious going on the stock would not be trading like it i
RDGL
maumar maumar 48 minutes ago
JPM: “ Despite raising our price target to reflect more value for future product royalties, we struggle to find a strong upside case from current levels that does not rely on giving even more credit. With the stock now at $62/sh, we are moving to the sidelines and lowering our rating to reflect HALO
JPM
PC retired PC retired 52 minutes ago
1776Rebel, you seem to be coming around to the truth. It's painful, but it is better to know than to remain under an illusion.
FLCX

Your Recent History

Delayed Upgrade Clock